A soluble CD4 protein selectively inhibits HIV replication and syncytium formation
- PMID: 2829023
- DOI: 10.1038/331078a0
A soluble CD4 protein selectively inhibits HIV replication and syncytium formation
Abstract
The CD4 (T4) molecule is expressed on a subset of T lymphocytes involved in class II MHC recognition, and is probably the physiological receptor for one or more monomorphic regions of class II MHC (refs 1-3). CD4 also functions as a receptor for the human immunodeficiency virus (HIV) exterior envelope glycoprotein (gp120) (refs 4-9), being essential for virus entry into the host cell and for membrane fusion, which contributes to cell-to-cell transmission of the virus and to its cytopathic effects. We have used a baculovirus expression system to generate mg quantities of a hydrophilic extracellular segment of CD4. Concentrations of soluble CD4 in the nanomolar range, like certain anti-CD4 monoclonal antibodies, inhibit syncytium formation and HIV infection by binding gp120-expressing cells. Perhaps more importantly, class II specific T-cell interactions are uninhibited by soluble CD4 protein, whereas they are virtually abrogated by equivalent amounts of anti-T4 antibody. This may reflect substantial differences in CD4 affinity for gp120 and class II MHC.
Similar articles
-
HIV infection is blocked in vitro by recombinant soluble CD4.Nature. 1988 Jan 7;331(6151):76-8. doi: 10.1038/331076a0. Nature. 1988. PMID: 2829022
-
Soluble CD4 molecules neutralize human immunodeficiency virus type 1.Nature. 1988 Jan 7;331(6151):84-6. doi: 10.1038/331084a0. Nature. 1988. PMID: 2829024
-
A soluble form of CD4 (T4) protein inhibits AIDS virus infection.Nature. 1988 Jan 7;331(6151):82-4. doi: 10.1038/331082a0. Nature. 1988. PMID: 3257544
-
Characterization of CD4 glycoprotein determinant-HIV envelope protein interactions: perspectives for analog and vaccine development.Crit Rev Immunol. 1988;8(4):315-39. Crit Rev Immunol. 1988. PMID: 2850890 Review.
-
The role of CD4 in HIV binding and entry.Philos Trans R Soc Lond B Biol Sci. 1993 Oct 29;342(1299):59-66. doi: 10.1098/rstb.1993.0136. Philos Trans R Soc Lond B Biol Sci. 1993. PMID: 7904348 Review.
Cited by
-
Current progress of RNA aptamer-based therapeutics.Front Genet. 2012 Nov 2;3:234. doi: 10.3389/fgene.2012.00234. eCollection 2012. Front Genet. 2012. PMID: 23130020 Free PMC article.
-
Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4.J Virol. 1989 Oct;63(10):4370-5. doi: 10.1128/JVI.63.10.4370-4375.1989. J Virol. 1989. PMID: 2550671 Free PMC article.
-
Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.BioDrugs. 2012 Dec 1;26(6):393-400. doi: 10.2165/11635350-000000000-00000. BioDrugs. 2012. PMID: 23046156 Free PMC article. Review.
-
Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4.J Virol. 1992 May;66(5):3125-30. doi: 10.1128/JVI.66.5.3125-3130.1992. J Virol. 1992. PMID: 1373203 Free PMC article.
-
The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle.J Virol. 1995 Oct;69(10):6304-13. doi: 10.1128/JVI.69.10.6304-6313.1995. J Virol. 1995. PMID: 7666531 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials